Hochrisikopatientin mit BRCA-1-Mutation – Risikofaktor Restdrüsengewebe nach prophylaktischer Mastektomie

Julia Téoule; Aba Harcos; Christof Sohn; Jörg Heil; Sarah Schott

doi:10.1055/s-0042-119611

Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents

Senologie - Zeitschrift für Mammadiagnostik und -therapie 2017; 14(01): 16-17
DOI: 10.1055/s-0042-119611

Interdisziplinäre Tumorkonferenz

Hochrisikopatientin mit BRCA-1-Mutation – Risikofaktor Restdrüsengewebe nach prophylaktischer Mastektomie

Authors

Julia Téoule
Aba Harcos
Christof Sohn
Jörg Heil
Sarah Schott

Abstract

Full Text

References

Literatur
1 Thompson DJ. et al. Research article Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer : the UK MARIBS study. Breast Cancer Research 2009; 11: 1-16
2 Baltzer HL. et al. MRI Volumetric Analysis of Breast Fibroglandular Tissue to Assess Risk of the Spared Nipple in BRCA1 and BRCA2 Mutation Carriers. Ann Surg Oncol 2014; 21: 1583-1588
3 van Verschuer VMT. Maijers MC. van Deurzen CHM. et al. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg 2015; 4: 467-475
4 Manning AT. et al. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance. Br J Surg 2015; 102: 1354-1359
5 Mavaddat N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822
6 Rhiem K. et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14: R156
7 Domchek SM. et al. Europe PMC Funders Group Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. JAMA 2010; 304: 967-975
8 Hartmann LC. Schaid DJ. Woods JE. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84
9 Rebbeck TR. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 2004; 22: 1055-1062
10 Meijers-Heijboer H. van Geel B. van Putten WL. et al. Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation. NEJM 2001; 345: 159-164
11 Yao K. Sisco M. Bedrosian I. Contralateral prophylactic mastectomy: current perspectives. Int J Womens Health 2016; 18: 213
12 Meindl A. Ditsch N. Kast K. et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108: 323-330
13 Heemskerk-Gerritsen BAM. et al. Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int J Cancer 2015; 136: 668-677